ERRα Inhibitors

The inhibitors listed target ERRα through various mechanisms. XCT790 and GSK5182 are direct and potent inverse agonists of ERRα. They bind to the receptor and induce a conformational change that reduces its transcriptional activity. Compounds like Diethylstilbestrol and 4-Hydroxytamoxifen, although primarily associated with estrogen receptors, can bind to ERRα due to structural similarities and modulate its activity. Bisphenol A, an environmental estrogen, also influences ERRα by binding to it. Other compounds like Tamoxifen, Clomiphene, and ICI 182,780 (Fulvestrant) are known for their roles in modulating estrogen receptors but have been found to interact with ERRα as well. Compound A is a specific antagonist of ERRα but is not fully characterized. 7-Ketocholesterol, an oxysterol, modulates ERRα activity through its interaction with the receptor. PF-06260414 and 2-Ethylhexyl 4-methoxycinnamate represent compounds that indirectly affect ERRα activity through unidentified pathways or broader systemic effects.

The inhibition of ERRα has implications in areas like metabolism, cardiovascular diseases, and cancer. ERRα is involved in the regulation of genes related to energy metabolism, making its inhibitors tools in metabolic disorder research. In cancer, where ERRα is often overexpressed, its inhibitors can help in understanding and controlling tumor growth and proliferation. The diverse mechanisms of these inhibitors highlight the complex interplay between nuclear receptors and their ligands, offering insights into how structural similarities and differences among receptors can be exploited for selective modulation. The use of these inhibitors is crucial in elucidating the physiological and pathological roles of ERRα, particularly in contexts where traditional estrogen receptor modulators may have limited efficacy.